Scholar Rock anticipates apitegromab approval by September 30 as FDA accepts SMA BLA with two fill-finish sites
Scholar Rock Holding Corporation Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $47.39
+5.9% in 3d after detection
Post-detection moves
1h
—
1d
+4.2%
3d
+5.9%
7d
+2.0%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS